[email protected]

国际内科前沿杂志

International Journal of Internal Medicine

您当前位置：首页 > 精选文章

International Journal of Internal Medicine. 2020; 1: (1) 6; 10.12208/j.ijim.20200007 .

Effect of tamoxifen and letrozole in the treatment of postmenopausal breast cancer and its influences on blood lipid metabolism
他莫昔芬与来曲唑治疗绝经后乳腺癌的疗效及对患者血脂代谢的影响

作者： 葛鹏, 李汉杰, 陈鑫, 景瑞军, 岳晚霞 *

西安医学院第二附属医院心胸外科

*通讯作者： 岳晚霞,单位：西安医学院第二附属医院心胸外科；

收录截图（CNKI-Scholar）

引用本文: 葛鹏, 李汉杰, 陈鑫, 景瑞军, 岳晚霞 他莫昔芬与来曲唑治疗绝经后乳腺癌的疗效及对患者血脂代谢的影响[J]. 国际内科前沿杂志, 2020; 1: (1) : 27-31.
Published: 2019/12/6 0:00:00

摘要

目的：比较他莫昔芬与来曲唑治疗绝经后乳腺癌的临床疗效及对患者血脂代谢的影响。方法：将本院收治的68例绝经后乳腺癌患者随机分为两组（n=34），A组应用他莫昔芬，B组应用来曲唑，对比两组治疗前后的血脂代谢、子宫内膜厚度、临床疗效等。结果：A组治疗后的TC、LDL-C水平明显降低，HDL-C水平明显升高（P<0.05），B组治疗前后的各项血脂代谢指标无明显变化（P>0.05）。A组治疗后的TC、LDL-C水平显著低于B组，HDL-C水平显著高于B组（P<0.05）。A组治疗1年、2年后的子宫内膜厚度值均显著高于B组（P<0.05）。 A组患者治疗后的子宫内膜增生总发生率显著高于B组，治疗总有效率显著低于于B组（P<0.05）。结论：来曲唑治疗绝经后乳腺癌的疗效优于他莫昔芬，同时还能够减少子宫内膜厚度，降低子宫内膜病变发生风险，他莫昔芬则能有效改善患者的血脂代谢情况。

关键词： 他莫昔芬；来曲唑；绝经后乳腺癌；血脂

Abstract

Objective: To compare the clinical efficacy of tamoxifen and letrozole in the treatment of postmenopausal breast cancer and its influences on the blood lipid metabolism.
Methods: 68 patients with postmenopausal breast cancer were randomly divided into two groups (n=34). The patients in group A were treated with tamoxifen and the patients in group B were treated with letrozole. Then compared the blood lipid metabolism, endometrial thickness, clinical efficacy and so on before and after treatment of two groups.
Results: The levels of TC and LDL-C in group A were significantly decreased and HDL-C levels were significantly increased after treatment (P<0.05). There was no significant change in all the lipid metabolism parameters before and after treatment in group B (P>0.05). The levels of TC and LDL-C in group A after treatment were significantly lower than those in group B, and the level of HDL-C was significantly higher than that in group B (P<0.05). The thickness of endometrium in group A was significantly higher than that in group B after treatment one year and two years (P<0.05). The total incidence of endometrial hyperplasia in group A was significantly higher than that in group B, and the total effective rate was significantly lower than that in group B (P<0.05).
Conclusion  : Letrozole is superior to tamoxifen in the treatment of postmenopausal breast cancer, while reducing the thickness of endometrium and reducing the risk of endometrial lesions. Tamoxifen can effectively improve the blood lipid metabolism in patients.

Key words： Tamoxifen; Letrozole; Postmenopausal breast cancer; Lipid metabolism

参考文献 References

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]